No Data
No Data
shanghai runda medical technology (603108.SH): launched AI large model all-in-one cabinet, with a leading advantage of light start and plug-and-play.
Gerong Hui, September 26th| Shanghai Runda Medical Technology (603108.SH) stated on the interactive platform that at the Huawei Full Connection Conference 2024, the company released an innovative AI doctor assistant solution called "Good Doctor". This solution is based on Huawei's Ascend lightweight training and calculation platform, combined with Shanghai Runda Medical Technology's large models and application capabilities, and introduced the AI large model integrated cabinet, with a leading advantage of lightweight startup and plug-and-play, better meeting the scenario-based needs of hospitals. It can empower doctors to improve diagnosis and treatment efficiency, as well as better benefit patients in enhancing the level of health management services.
shanghai runda medical technology (603108.SH): Launched the personal AI health assistant smart body “Xiao Hui” on September 10th.
Gelonghui September 26 | shanghai runda medical technology (603108.SH) stated on the interactive platform that on September 10, it launched the individual AI health assistant intelligence body 'Xiaohui'. Currently, the Xiaohui app developed based on the Android system has been launched and is in the public testing phase, while the app's Hongmeng development certification is also in progress.
Subdued Growth No Barrier To Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Price
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Shanghai Runda Medical Technology (603108.SH): The net income for the first half of the year was 91.3061 million yuan, a year-on-year decrease of 47.82%.
Shanghai Runda Medical Technology (603108.SH) released its semi-annual report on August 28. During the reporting period, the company achieved a total revenue of 4.135 billion yuan, a decrease of 8.54% compared to the same period last year. This is mainly due to the impact of the medical policy environment during the reporting period, which has affected the development of customers in various levels of medical institutions and led to a slight decrease in the company's business revenue compared to the same period last year. The company's net income attributable to shareholders during the reporting period was 91.3061 million yuan, a decrease of 47.82% compared to the same period last year. This is mainly due to the decrease in operating income during the reporting period, while the company's gross margin remained stable and fixed expenses such as personnel remained unchanged.
No Data
No Data